Skip to main content
. 2022 Dec 13;12(12):2092. doi: 10.3390/life12122092

Figure 5.

Figure 5

Ang-2 serum levels of patients at the third cycle of chemotherapy. (A) Ang-2 serum levels of NSCLC patients who received PBC in combination with anti-VEGF before treatment and after the third cycle of chemotherapy. (B) Ang-2 serum levels of SCLC patients who received PBC before treatment and after the third cycle of chemotherapy.